Andrew Vaillant is the inventor of Replicor’s NAP technology and has more than 15 years of experience in viral biology, antiviral drug development and nucleic acid chemistry. He has authored numerous publications and patents on the development and use of NAPs as agents to treat infectious diseases. He previously held positions at two biotechnology companies in Montreal. He was a Postdoctoral Fellow at the Montreal Neurological Institute and holds a PhD in Cell Biology from the University of Ottawa, Canada. Andrew Vaillant is the inventor of Replicor’s NAP technology and has more than 15 years of experience in viral biology, antiviral drug development and nucleic acid chemistry. He has authored numerous publications and patents on the development and use of NAPs as agents to treat infectious diseases. He previously held positions at two biotechnology companies in Montreal. He was a Postdoctoral Fellow at the Montreal Neurological Institute and holds a PhD in Cell Biology from the University of Ottawa, Canada.
Gastroenterology